Show simple item record

dc.contributor.authorHorsch, D
dc.contributor.authorAnthony, L
dc.contributor.authorGross, D
dc.contributor.authorValle, Juan W
dc.contributor.authorWelin, S
dc.contributor.authorBenavent, M
dc.contributor.authorKassler-Taub, K
dc.contributor.authorBinder, P
dc.contributor.authorBanks, P
dc.contributor.authorJackson, S
dc.contributor.authorPerez-Olle, R
dc.contributor.authorKulke, M
dc.date.accessioned2019-04-29T09:49:00Z
dc.date.available2019-04-29T09:49:00Z
dc.date.issued2019en
dc.identifier.citationHorsch D, Anthony L, Gross D, Valle JW, Welin S, Benavent M, et al. Long-term treatment with telotristat ethyl (TE) in patients with carcinoid syndrome (CS) symptoms: results from TELEPATH study. Neuroendocrinology. 2019;108:183.en
dc.identifier.urihttp://hdl.handle.net/10541/621793
dc.language.isoenen
dc.titleLong-term treatment with telotristat ethyl (TE) in patients with carcinoid syndrome (CS) symptoms: results from TELEPATH studyen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentZentralklinik Bad Berka GmbH, CA Gastroenterologie, Bad Berka, Germanyen
dc.identifier.journalNeuroendocrinologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record